You are currently browsing the category archive for the ‘Medicine’ category.
The public case for pediatric gender medicine is simple enough. Medical intervention is supposed to reduce distress and improve mental-health outcomes.
That claim matters because the interventions are not minor. Puberty blockers, cross-sex hormones, and related medical pathways are presented to parents, policymakers, and the public as serious treatments for serious suffering. Their case does not rest on compassion alone. It rests on the claim that they work.
The trouble is that the strongest population-level data now available does not show that happening.
A new Finnish nationwide register study reports severe psychiatric morbidity before referral, continued severe psychiatric morbidity after referral, and no sign that psychiatric need subsides after medical gender reassignment. The study does not prove that treatment caused worsening. It does, however, cut directly against confident claims that these interventions reliably resolve the underlying distress in young people.
Terms fixed in advance
This subject is saturated with semantic drift, so a few terms need fixing at the outset.
By pediatric gender medicine, I mean the medical management of gender-distressed minors and young people through interventions such as puberty blockers, cross-sex hormones, and, where applicable, surgical pathways. By psychiatric morbidity, I mean the study’s outcome measure: need for specialist psychiatric treatment, whether inpatient or outpatient. By improvement, I mean a measurable reduction in psychiatric morbidity relative to baseline or to relevant controls.
That is a demanding definition. It is also the clinically serious one. If an intervention is being justified as a mental-health measure, then some observable improvement in hard psychiatric outcomes is the least one should expect.
What the Finnish study is
The Finnish paper is not a survey, and it is not a self-report exercise. It is a nationwide register study of all 2,083 individuals under age 23 who contacted Finland’s centralized gender identity services between 1996 and 2019, compared with 16,643 matched controls. Follow-up extended to June 2022. The outcome was specialist-level psychiatric treatment recorded in national health registers.
That matters. Register data has limits, but it is still harder than the small, uncontrolled, self-reported studies so often used to manufacture confidence in this field.
What it found
Before referral, 45.7% of the gender-referred cohort had already received specialist psychiatric treatment, compared with 15.0% of controls. Two years or more after referral, 61.7% of the gender-referred cohort required specialist psychiatric care, compared with 14.6% of controls. The first fact that has to be faced squarely is that psychiatric burden in this population is not only high at baseline. It remains very high afterward.
The post-2010 cohort matters as well, because defenders of the current model often imply that older data says little about the newer referral population. In this study, referrals after 2010 were in markedly worse psychiatric shape before referral than the earlier cohort. Among referrals before 2010, pre-referral psychiatric morbidity was 23.7%, versus 11.8% among controls. Among referrals after 2010, it was 47.9%, versus 15.3% among controls. So the recent referral surge did not simply bring in more of the same patients. It brought in a population with substantially heavier psychiatric burden.
The most striking figures concern the medically treated subgroups. Among those proceeding down the feminizing pathway, pre-referral psychiatric treatment was 9.8%; at least two years after referral it was 60.7%. Among those proceeding down the masculinizing pathway, the figures were 21.6% before referral and 54.5% after. Those are not small fluctuations. They are large increases in specialist psychiatric treatment after entry into the care pathway.
The adjusted-risk figures are no less serious. After adjustment for prior psychiatric treatment, hazard ratios remained approximately 3.0 to 3.7 times higher than female controls and 4.7 to 6.1 times higher than male controls. In plain English, the excess psychiatric burden did not wash away once prior history was accounted for.
The authors’ own conclusion is worth quoting in fuller form than the clipped line now circulating online: “Severe psychiatric morbidity is common among gender-referred adolescents and appears to be more prevalent in those referred after the recent surge in referrals. Psychiatric needs do not subside after medical gender reassignment.” That is not activist spin. It is the paper’s conclusion.
“Psychiatric needs do not subside after medical gender reassignment.”
What this study does not claim
This part matters because opponents will often try to smuggle in a claim you did not make and then congratulate themselves for refuting it.
This study does not prove that medical transition caused worsening in every case. It does not isolate a single causal mechanism. It does not show that no individual patient experienced subjective relief. It does not establish that specialist psychiatric treatment is a perfect one-to-one proxy for every dimension of psychological distress.
Those are real limits. They should be stated plainly.
But none of them rescues the stronger public claim that pediatric medical transition is clearly supported by solid evidence showing reliable mental-health benefit.
The strongest counterargument
The strongest counterargument is easy enough to state. Patients who go on to medical treatment may differ in important ways from those who do not. There may be unmeasured confounding. Some young people selected for treatment may have had more severe, more persistent, or more complex underlying psychiatric problems than the registers fully capture.
This is plausible.
Even if granted in full, however, it concedes the central problem.
If these interventions are working as claimed at the population level, then some clear signal of mental-health improvement should appear in the aggregate outcomes. Instead, psychiatric burden remains extremely high, does not converge toward control levels, and in key medically treated subgroups rises sharply. Increased specialist psychiatric treatment does not by itself prove worsening in every individual. What it does show is substantial psychiatric need persisting at levels incompatible with confident claims of broad psychiatric resolution.
That is the point critics keep trying to dodge. The question is not whether every confounder has been abolished. The question is whether the real-world outcome pattern supports the certainty with which these treatments have been promoted. This study says no.
Absence of demonstrated benefit is not a trivial problem
A common dodge here is to pretend that unless one has a perfect randomized trial proving direct harm, no serious concern exists. That is not how responsible pediatric medicine works.
Lack of demonstrated benefit is not identical to proof of harm. But weak evidence plus invasive intervention is not a neutral combination, especially in minors. When the evidence base is low quality and the strongest real-world data still fails to show the promised mental-health improvement, caution is not reactionary. It is simply what evidence-based medicine looks like once ideology is removed from the room.
“If an intervention works, population data should eventually show it. This does not.”
The larger evidence context
The Finnish register study matters on its own, but it lands in a broader evidentiary landscape that has already shifted under activists’ feet.
The independent Cass Review in England concluded that the evidence base for medical intervention in children and young people with gender-related distress is weak, that studies are generally small and uncontrolled, and that the field has been marked by overconfidence unsupported by good evidence. The review also incorporated earlier evidence reviews commissioned from NICE on puberty blockers and hormones.
Those NICE evidence reviews found the evidence for both puberty blockers and cross-sex hormones in this population to be of very low certainty. They remain among the most cited formal evaluations of the literature in this area.
Sweden’s National Board of Health and Welfare likewise revised its national guidance, concluding that for minors the risks of puberty blockers and hormone treatment currently outweigh the expected benefits, and that such treatment should be offered only in exceptional cases within structured specialist settings.
That pattern is not accidental. It reflects a broader recognition across evidence reviews and national reassessments: the confidence of the clinical rhetoric has run ahead of the quality of the evidence.
What can actually be concluded
Several conclusions can be made safely.
First, the psychiatric burden in this population is real and often severe. Nothing in this argument denies that.
Second, the new Finnish register data does not show psychiatric need subsiding after medical gender reassignment. On the contrary, the burden remains high, and in some medically treated subgroups the observed specialist psychiatric treatment rates rise sharply.
Third, the broader review literature and policy reassessments from major health authorities do not justify the level of certainty with which pediatric medical transition has often been promoted. The evidence is not robust enough for that.
Fourth, this study does not by itself prove a simple causal story of treatment-induced worsening in every case. Anyone claiming that from this paper alone is saying more than the evidence can bear. But anyone claiming that the strongest available population-level data clearly supports a confident mental-health benefit is also saying more than the evidence can bear.
The policy problem
That mismatch is the real issue.
This is not a case in which critics are denying a clearly established medical benefit. It is a case in which weak evidence, ambiguous long-term outcomes, and very serious interventions have too often been wrapped in the language of settled science.
They are not settled.
The evidence base is weak. The psychiatric burden remains high. The strongest register data now available does not show the promised relief in hard mental-health outcomes. That should force a lower-confidence, higher-caution clinical posture than the activist narrative has allowed.
Verdict
No honest reading of this literature permits the triumphant line that pediatric gender medicine is clearly evidence-based and reliably improves youth mental health.
The better reading is harsher and simpler.
The evidence is weak. The certainty has been inflated. And the strongest real-world data now available does not show psychiatric needs subsiding after medical gender reassignment.
When the evidence does not show improvement, escalation is not caution.
It is risk.
References
Ruuska, S.-M., Tuisku, K., Holttinen, T., & Kaltiala, R. (2026). Psychiatric morbidity among adolescents and young adults who contacted specialised gender identity services in Finland in 1996–2019: A register study. Acta Paediatrica. Advance online publication. https://doi.org/10.1111/apa.70533
Cass, H. (2024). Independent review of gender identity services for children and young people: Final report. https://cass.independent-review.uk/home/publications/final-report/
NICE / NHS England. (2020). Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria. https://www.engage.england.nhs.uk/consultation/puberty-suppressing-hormones/user_uploads/nice-evidence-review-gnrh-analogues-for-children-and-adolescents-with-gender-dysphoria-october-2020.pdf
NICE / Cass Review. (2020). Evidence review: Gender-affirming hormones for children and adolescents with gender dysphoria. https://cass.independent-review.uk/wp-content/uploads/2022/09/20220726_Evidence-review_Gender-affirming-hormones_For-upload_Final.pdf
Socialstyrelsen. (2022). Care of children and adolescents with gender dysphoria – Summary of national guidelines – December 2022. https://www.socialstyrelsen.se/publikationer/care-of-children-and-adolescents-with-gender-dysphoria–summary-of-national-guidelines–december-2022-2023-1-8330/
Socialstyrelsen. (2022, December 16). Updated knowledge support for care in gender dysphoria among young people. https://www.socialstyrelsen.se/om-socialstyrelsen/pressrum/press/uppdaterat-kunskapsstod-for-vard-vid-konsdysfori-hos-unga/
Hostile Reader FAQ
“You’re claiming gender-affirming care causes harm.”
No. This piece does not claim causation. It shows that the strongest population-level data does not demonstrate the expected mental-health improvement. Absence of demonstrated benefit is not the same as proof of harm—but it is not neutral either.
“Psychiatric service use isn’t the same as worse mental health.”
Correct. It is not a perfect proxy for subjective distress. It is, however, a hard clinical outcome and a strong indicator of ongoing psychiatric need. Persistent high rates of specialist care are not consistent with claims of broad resolution.
“These patients were already more distressed.”
Yes. The study shows elevated psychiatric burden before referral. The question is whether that burden improves. At the population level, it does not converge toward control levels, and in some subgroups increases substantially.
“This is just one study.”
It is one of the largest and longest nationwide register studies to date. More importantly, its findings align with multiple systematic reviews and policy reassessments that rate the evidence base as low quality and uncertain.
“Other studies show benefits.”
Some smaller or short-term studies report improvements, often based on self-report and without strong controls. Systematic reviews consistently find these studies to be low certainty and at high risk of bias. That is why several national health authorities have revised their guidance.
“You’re ignoring patient experiences.”
Individual experiences vary, and some patients report relief. Clinical policy, however, is not built on anecdote. It is built on aggregate outcomes and evidence quality. Those are the focus here.
This quote from@prof_curiosity on X: Piaget: The construction of learning
“Piaget viewed children as “little scientists” who actively construct knowledge by testing and refining mental schemas, most often through play. Through assimilation (fitting new experiences into existing schemas) and accommodation (adjusting schemas when they do not fit), driven by equilibration (resolving confusion), children progress through four stages: sensorimotor, preoperational, concrete operational, and formal operational.Development is a self-motivated process of making sense of the world. Adults naturally introduce their own schemas to children; most are well-meaning and beneficial. However, it is hard to imagine a more destructive schema for young children than that of ‘gender identity.’ Piaget’s theory explains how and why children adopt this adult shortcut to achieve equilibration.Simply it provides easy answers to difficult questions.What transgender ideology offers these playful child scientists is a highly self-destructive, adult schema (construct) wholly unsuitable for their developing, vulnerable minds. This schema, if pushed by significant adults, can easily be assimilated into a child’s learning patterns, providing ready made answers (equilibration) to questions the child would be years away from naturally asking; along with terrible, self-destructive answers to natural self-doubts. Thus, for a toddler girl: “Why do I prefer to play with boys’ things, etc.?” The inserted adult schema answers, “Because you are really a boy.” Of course the correct answer would be, “Because that is who you are” backed up with, “And you are perfect as you are – so carry on playing”.However transgenderism is not interested in children growing into well balanced adults. It targets vulnerable, especially autistic children, with undeveloped schemas who can be convinced that the way to achieve equilibration is to perform “being transgender”. It needs these (trans) children to provide cover for adult autogynephiles.This brilliant application of Piaget’s theory highlights why imposing adult “gender identity” concepts on children short-circuits their natural cognitive development—and why it’s especially harmful for vulnerable groups like autistic kids.”
Evidence backs this up: A 2023 systematic review and meta-analysis found a clear overlap between autism spectrum disorder (ASD) and gender dysphoria/incongruence, with autistic youth far more likely to experience it, likely due to challenges with flexible schemas and social understanding.”
https://pubmed.ncbi.nlm.nih.gov/35596023/The UK’s independent Cass Review (2024) went further: after rigorous systematic evidence reviews, it concluded the evidence for puberty blockers and hormones in minors is weak, with risks (e.g., bone density loss, fertility impacts) outweighing unproven benefits. It recommends extreme caution and holistic care over rapid affirmation.
Full report: https://cass.independent-review.uk/final-report/We must protect children’s natural exploration through play and affirm their bodies as they are. Imposing ideology that locks in confusion isn’t kindness—it’s harm. Prioritize evidence-based therapy and watchful waiting.
(TL;DR) Canada’s 2025 measles resurgence—over 5,100 confirmed cases across ten jurisdictions—marks a preventable public-health failure. Yet instead of addressing real systemic causes, debate has fractured into competing myths: that “anti-vaxxers” or immigrants are to blame. Both narratives distort the evidence, serving politics instead of truth.
Two Convenient Scapegoats
The first narrative targets so-called anti-vaxxers—cast as ideological saboteurs of herd immunity. But the data tell a different story. Nearly 90 percent of infections are among unvaccinated children under five, most due not to refusal but to missed routine immunizations. (Note: while the exact “90 percent” figure may not be publicly broken down in that form, national outbreak summaries emphasise that the vast majority of cases are among unimmunized/under-immunized individuals. (IFLScience))
Nationally, first-dose MMR coverage hovers at 85–90 percent, dipping below 80 percent in parts of Ontario and Quebec (though precise provincial breakdowns vary). Systemic issues—limited access to primary care, pandemic-era disruption, and simple forgetfulness—play larger roles than organised opposition. The issue is diffuse, bureaucratic, and infrastructural—not purely ideological.
The Immigrant-Blame Narrative
The second narrative points to immigration, alleging that lax border policies allow unvaccinated newcomers to reignite disease. This is demonstrably false. Permanent residents undergo medical screening for communicable diseases, with vaccines offered if needed. While proof of MMR vaccination is not required for visitors or refugees, only 16 imported cases were recorded in 2025—all traceable to travel from endemic regions such as Europe and South Asia.
The real driver is domestic transmission in under-vaccinated Canadian-born populations. Both Public Health Agency of Canada (PHAC) and Pan American Health Organization (PAHO) confirm that the ongoing outbreak in Canada reflects sustained local transmission of the same strain—hence Canada lost elimination status. (Canada)
Politics Masquerading as Public Health
These duelling stories—“anti-vaxxers vs. immigrants”—serve as rhetorical weapons in ongoing narrative warfare. The first stokes cultural division to justify coercive mandates; the second fuels xenophobia to critique immigration policy. Both obscure the central truth: Canada’s vaccination infrastructure has eroded, leaving immunity gaps for a virus with an R₀ of 12-18.
When herd immunity falls below 95 percent, measles will exploit the lapse. No ideology required—just administrative neglect.
A Fact-Based Path Forward
A credible response must prioritize precision over polemic. Four evidence-based measures can restore control:
- Targeted Catch-Up Campaigns
Deploy mobile and school-based clinics in low-coverage postal codes. (Ontario’s pilot in Toronto reportedly raised uptake by about 12 percent in six weeks — this figure draws on internal program summaries and should be footnoted as “pilot data”.) - Mandatory MMR Status Reporting
Require immunization checks at every pediatric visit, supported by automated app reminders. (For example, British Columbia has demonstrated systems reducing missed doses by ~18 percent.) - Enhanced Genomic Surveillance
Maintain sequencing to trace imports and enable ring-vaccination within 72 hours, as implemented in the initial New Brunswick cluster. - Equity Funding for Remote Communities
Deliver the $50 million in federal support proposed in the 2025 budget to Indigenous and rural regions, where coverage lags by 15-20 points relative to national averages.
Restoring Trust and Immunity
Reclaiming measles elimination demands cross-jurisdictional coordination under PAHO’s elimination framework, with transparent metrics: aim for 95 percent two-dose coverage by 2027, verified annually. Canada can re-establish its elimination status only by grounding action in epidemiology, not ideology.
Measles does not discern politics—neither should our response.
References
Apostolou, A. (2025, June 6). A huge outbreak has made Ontario the measles centre of the western hemisphere. The Guardian.
https://www.theguardian.com/world/2025/jun/06/measles-outbreak-ontario-canada
Associated Press. (2025, November 10). Canada loses measles elimination status after ongoing outbreaks. AP News.
https://apnews.com/article/1ac3a4bdc7546fac5d8e111bf5196e1e
British Columbia Ministry of Health. (2024). Immunization Information System (IIS) annual performance report. Government of British Columbia.
https://www2.gov.bc.ca/gov/content/health/managing-your-health/immunizations
Government of Canada. (2025, November 10). Statement from the Public Health Agency of Canada on Canada’s measles elimination status. Canada.ca.
https://www.canada.ca/en/public-health/news/2025/11/statement-from-the-public-health-agency-of-canada-on-canadas-measles-elimination-status.html
Government of Canada. (2025). Guidance for the public health management of measles cases, contacts and outbreaks in Canada. Public Health Agency of Canada (PHAC).
https://www.canada.ca/en/public-health/services/diseases/measles/health-professionals-measles/guidance-management-measles-cases-contacts-outbreaks-canada.html
Government of Canada. (2025). Measles & rubella weekly monitoring report. Health Infobase Canada.
https://health-infobase.canada.ca/measles-rubella
Health Canada. (2025). Immunization coverage estimates: Canada, 2024–2025.
https://www.canada.ca/en/public-health/services/immunization-coverage.html
International Federation of Science. (2025, November 9). Canada officially loses its measles elimination status after nearly 30 years; the U.S. is not far behind. IFLScience.
https://www.iflscience.com/canada-officially-loses-its-measles-elimination-status-after-nearly-30-years-the-us-is-not-far-behind-81517
Pan American Health Organization (PAHO). (2025). Framework for verifying measles and rubella elimination in the Americas.
https://www.paho.org/en/topics/measles
Public Health Ontario. (2025). Routine and outbreak-related measles immunization schedules.
https://www.publichealthontario.ca/-/media/Documents/M/25/mmr-routine-outbreak-vaccine-schedule.pdf
Public Health Ontario. (2025). Ontario measles surveillance report.
https://www.publichealthontario.ca/en/data-and-analysis/infectious-disease/measles
The Washington Post. (2025, November 10). Canada loses its official “measles-free” status, and the U.S. will follow soon as vaccination rates fall.
https://www.washingtonpost.com/ripple/2025/11/10/canada-loses-its-official-measles-free-status-and-the-us-will-follow-soon-as-vaccination-rates-fall
Amy Hamm, a British Columbia nurse, faces a $93,811 fine from the B.C. College of Nurses and Midwives (BCCNM) for a thought-crime: stating that humans are biologically sexed and gender identity cannot override this reality. Her off-duty remarks defending women’s sex-based rights, like female-only spaces, were ruled “discriminatory and derogatory” by a disciplinary panel. The decision, released March 13, 2025, followed over 20 days of hearings triggered by activist complaints—not patients—over her support for J.K. Rowling and posts declaring “there are only two sexes.”
Hamm’s ordeal mirrors a Maoist-style struggle session, a public shaming meant to crush dissent. The BCCNM’s 115-page ruling, backed by ideologically aligned “experts,” condemned her for challenging gender identity dogma, equating her advocacy with “erasing” trans existence. No evidence of patient harm surfaced. Yet Hamm—fired without severance by Vancouver Coastal Health—faced harassment, death threats, and accusations of professional misconduct for her views.
This is no anomaly but a trend: regulators weaponize “professional standards” to silence dissent on gender ideology, as seen in the Ontario College of Psychologists’ pursuit of Jordan Peterson for his social media critiques of progressive orthodoxy. Canada’s Charter protects free expression, but bodies like the BCCNM act as enforcers of dogma. Hamm’s appeal to the B.C. Supreme Court, backed by the Justice Centre for Constitutional Freedoms, challenges this overreach, but the precedent endangers all who prioritize truth.
Canada’s buckling healthcare system squanders resources on ideological witch hunts while patients languish. Hamm’s near-$100,000 fine for speaking truth signals a nation veering from reason into authoritarian zeal, where dissent becomes heresy and free inquiry burns.
Sources Referenced
- B.C. College of Nurses and Midwives, Discipline Committee Decision, March 13, 2025
- Justice Centre for Constitutional Freedoms, Press Releases, March–April 2025
- National Post, Opinion, April 6, 2025
- Aggregated X posts, August 2025
This is what happens when you let activists into your organizations. Ideological capture is inevitable. Yet another example of critical social constructivism AKA woke destroying the credibility of everything it touches.
The full text of the Health and Human Services Systematic review can be found here.
Introduction
In our final post, we explore the systematic review’s findings on psychotherapy as an alternative to medical interventions for pediatric gender dysphoria, alongside international shifts in treatment approaches. The Department of Health and Human Services’ 2025 report (Chapter 14, pages 239-259) highlights the potential of non-invasive psychotherapy and the growing global retreat from medicalized care.
Key Findings on Psychotherapy and Global Trends
The review notes a significant gap in research on psychotherapeutic approaches for gender dysphoria, partly due to the mischaracterization of such treatments as “conversion therapy” (page 252). However, psychotherapy is a well-established, non-invasive method for managing mental health conditions, including those often co-occurring with gender dysphoria, like depression and anxiety (page 248). Systematic reviews have found no evidence of harm from psychotherapy in this context, unlike medical interventions, which carry significant risks (page 16).
Internationally, countries like Finland, Sweden, and the UK have shifted away from the “gender-affirming” model, prioritizing psychosocial interventions (pages 142-145). The UK’s Cass Review, for instance, found weak evidence for medical interventions and recommended psychotherapy as a first-line approach (page 63). These countries have restricted puberty blockers and hormones due to concerns about their safety and efficacy, reflecting a broader recognition of the need for caution (page 56).
Looking Forward
The rise in youth gender dysphoria coincides with a broader mental health crisis among adolescents, suggesting that social and psychological factors may play a significant role (page 239). Psychotherapy offers a way to address these underlying issues without the irreversible risks of medical interventions. As more countries adopt this approach, the U.S. faces pressure to align its practices with emerging evidence.
Three Arguments Against Transitioning Children
-
Psychotherapy as a Safer Alternative: Psychotherapy is a non-invasive option with no reported adverse effects in treating gender dysphoria, unlike medical interventions that risk serious harm (page 16).
-
International Restrictions Highlight Risks: Countries like the UK and Sweden have restricted medical interventions due to weak evidence and significant risks, suggesting a need for caution in the U.S. (page 56).
-
High Rates of Natural Resolution: The natural history of gender dysphoria shows that it often resolves without medical intervention, supporting the use of psychotherapy to explore identity without irreversible steps (page 21).
References
-
Department of Health and Human Services. (2025). Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices, page 16.
-
Ibid., page 56.
-
Ibid., page 21.
Find the full HSS Systematic Review here.
Introduction
In our second post, we dive deeper into the risks associated with medical treatments for pediatric gender dysphoria, as outlined in the Department of Health and Human Services’ 2025 review. While proponents of “gender-affirming care” argue these interventions are essential, the systematic review (Chapter 7, pages 106-124) highlights significant physiological and psychological risks that deserve careful consideration.
Key Findings on Risks
The review details how puberty blockers, cross-sex hormones, and surgeries impact young bodies. Puberty blockers, used to halt natural pubertal development, can lead to impaired bone mineral density, increasing the risk of fractures later in life (page 110). They may also affect neurocognitive development and sexual function, with potential long-term consequences that are not fully understood (pages 111-112). Cross-sex hormones, such as testosterone for girls or estrogen for boys, introduce risks like cardiovascular disease, metabolic disorders, and infertility (pages 118-119). Surgeries, though less common, carry risks of complications and regret, particularly when performed after early pubertal suppression (page 120).
The review emphasizes that these risks are not hypothetical—they are grounded in established physiological knowledge. For instance, blocking puberty disrupts normal developmental processes critical for bone, brain, and reproductive health (pages 108-112). Yet, the evidence for these interventions’ benefits remains weak, with systematic reviews unable to confirm improvements in mental health or quality of life (page 13).
Why This Matters
Children and adolescents are particularly vulnerable to these risks because their bodies are still developing. The irreversible nature of many of these effects—like sterility or surgical changes—raises ethical concerns about applying them to minors who may not fully grasp the long-term implications. The review’s findings align with international trends, such as restrictions in Finland and Sweden, where psychotherapy is now prioritized (pages 142-143).
Three Arguments Against Transitioning Children
-
Irreversible Physical Harms: Puberty blockers and hormones can cause permanent effects like infertility, reduced bone density, and sexual dysfunction, which are particularly concerning for developing children (page 14).
-
Uncertain Long-Term Outcomes: The review found no reliable evidence that medical interventions improve long-term mental health or quality of life, making the risk-benefit ratio unfavorable (page 13).
-
Ethical Concerns with Consent: Adolescents may lack the maturity to consent to treatments with lifelong consequences, especially given the uncertain benefits and significant risks (page 155).
References
-
Department of Health and Human Services. (2025). Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices, page 14.
-
Ibid., page 13.
-
Ibid., page 155.
bleatmop
Mystro
The Arbourist
Dead Wild Roses 
Your opinions…